ANNEX III
Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1)
Part 1 is amended as follows:
(a)
in point 1.1.3.1, the following notes V and W are added:
‘Note V:
If the substance is to be placed on the market as fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) or particles of the substance fulfilling the WHO fibre criteria or as particles with modified surface chemistry, their hazardous properties must be evaluated in accordance with Title II of this Regulation, to assess whether a higher category (Carc. 1B or 1A) and/or additional routes of exposure (oral or dermal) should be applied.’
Note W:
‘It has been observed that the carcinogenic hazard of this substance arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.
This note aims to describe the particular toxicity of the substance; it does not constitute a criterion for classification according to this Regulation.’;
(b)
in point 1.1.3.2, the following note 10 is added:
‘Note 10:
The classification as a carcinogen by inhalation applies only to mixtures in powder form containing 1 % or more of titanium dioxide which is in the form of or incorporated in particles with aerodynamic diameter ≤ 10 μm.’;
(2)
in Part 3, Table 3 is amended as follows:
(a)
the rows with index numbers 604-083-00-X and 611-159-00-6 are deleted;
(b)
the rows corresponding to index numbers 015-189-00-5, 027-001-00-9, 028-018-00-4, 603-023-00-X, 605-005-00-7, 606-047-00-9, 607-232-00-7, 607-247-00-9, 608-039-00-0, 613-054-00-0, 616-018-00-2 and 648-055-00-5 are replaced by the following rows respectively:
Index No
Chemical name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘015-189-00-5
phenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide
423-340-5
162881-26-7
Skin Sens. 1A
Aquatic Chronic 4
H317
H413
GHS07
Wng
H317
H413’
‘027-001-00-9
cobalt
231-158-0
7440-48-4
Carc. 1B
Muta. 2
Repr. 1B
Resp. Sens. 1
Skin Sens. 1
Aquatic Chronic 4
H350
H341
H360F
H334
H317
H413
GHS08
Dgr
H350
H341
H360F
H334
H317
H413’
‘028-018-00-4
nickel bis(sulfamidate);
nickel sulfamate
237-396-1
13770-89-3
Carc. 1A
Muta. 2
Repr. 1B
Acute Tox. 4
STOT RE 1
Resp. Sens. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H350i
H341
H360D***
H302
H372**
H334
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H350i
H341
H360D***
H302
H372**
H334
H317
H410
oral: ATE = 853 mg/kg bw (anhydrate)
oral: ATE = 1098 mg/kg bw (tetrahydrate)
STOT RE 1;
H372: C ≥ 1 %
STOT RE 2;
H373: 0,1 % ≤ C < 1 %
Skin Sens. 1;
H317: C ≥ 0,01 %
M = 1’
‘603-023-00-X
ethylene oxide;
oxirane
200-849-9
75-21-8
Flam. Gas 1
Press. Gas
Carc. 1B
Muta. 1B
Repr. 1B
Acute Tox. 3
Acute Tox. 3
STOT SE 3
STOT SE 3
STOT RE 1
Skin Corr. 1
Eye Dam. 1
H220
H350
H340
H360Fd
H331
H301
H335
H336
H372 (nervous system)
H314
H318
GHS02
GHS08
GHS06
GHS05
Dgr
H220
H350
H340
H360Fd
H331
H301
H335
H336
H372 (nervous system)
H314
inhalation: ATE = 700ppm (gases)
oral: ATE = 100 mg/kg bw’
U
‘605-005-00-7
metaldehyde (ISO);
2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane
203-600-2
108-62-3
Flam. Sol. 2
Repr. 2
Acute Tox. 3
Aquatic Chronic 3
H228
H361f
H301
H412
GHS02
GHS08
GHS06
Dgr
H228
H361f
H301
H412
oral: ATE = 283 mg/kg bw’
‘606-047-00-9
2-benzyl-2-dimethylamino-4'-morpholinobutyrophenone
404-360-3
119313-12-1
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410’
‘607-232-00-7
pyridate (ISO);
O-(6-chloro-3-phenylpyridazin-4-yl) S-octyl thiocarbonate
259-686-7
55512-33-9
Acute Tox. 4
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H315
H317
H400
H410
GHS07
GHS09
Wng
H302
H315
H317
H410
oral: ATE = 500 mg/kg bw
M = 1
M = 10’
‘607-247-00-9
dodecyl methacrylate
205-570-6
142-90-5
STOT SE 3
H335
GHS07
Wng
H335
STOT SE 3; H335: C ≥ 10 %’
‘608-039-00-0
2-phenylhexanenitrile
423-460-8
3508-98-3
Acute Tox. 4
Aquatic Chronic 2
H302
H411
GHS07
GHS09
Wng
H302
H411
oral:
ATE = 500 mg/kg bw’
‘613-054-00-0
thiabendazole (ISO);
2-(thiazol-4-yl)benzimidazole
205-725-8
148-79-8
Aquatic Acute 1 Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 1’
‘616-018-00-2
diethyltoluamide (ISO): N,N-diethyl-m-toluamide; [deet]
205-149-7
134-62-3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
H302
H315
H319
GHS07
Wng
H302
H315
H319
oral:
ATE = 1892 mg/kg bw’
(c)
the following rows are inserted:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘022-006-002
titanium dioxide;
[in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm]
236-675-5
13463-67-7
Carc. 2
H351 (inhalation)
GHS08
Wng
H351 (inhalation)
V, W, 10’
‘080-012-00-0
methylmercuric chloride
204-064-2
115-09-3
Carc. 2
Repr. 1A
Lact.
Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H360Df
H362
H330
H310
H300
H372 (nervous system, kidneys)
H400
H410
GHS08
GHS06
GHS09
Dgr
H351
H360Df
H362
H330
H310
H300
H372 (nervous system, kidneys)
H410
inhalation: ATE = 0,05 mg/l (dusts or mists)
dermal: ATE = 50 mg/kg bw
oral: ATE = 5 mg/kg bw
1’
‘601-090-00-X
benzo[ rst ]pentaphene
205-877-5
189-55-9
Carc. 1B
Muta. 2
H350
H341
GHS08
Dgr
H350
H341’
‘601-091-00-5
dibenzo[ b,def ]chrysene;
dibenzo[ a , h ]pyrene
205-878-0
189-64-0
Carc. 1B
Muta. 2
H350
H341
GHS08
Dgr
H350
H341’
‘603-236-00-8
ethanol, 2,2’-iminobis-, N -(C13-15-branched and linear alkyl) derivs.
308-208-6
97925-95-6
Repr. 1B
H360D
GHS08
Dgr
H360D’
‘607-733-00-0
cyflumetofen (ISO);
2-methoxyethyl ( RS )-2-(4- tert -butylphenyl)-2-cyano-3-oxo-3-(α,α,α-trifluoro- o -tolyl)propionate
—
400882-07-7
Carc. 2
Skin Sens. 1A
H351
H317
GHS08
GHS07
Wng
H351
H317’
‘607-734-00-6
pentapotassium 2,2’,2’’,2’’’,2’’’’-(ethane-1,2-diylnitrilo)pentaacetate
404-290-3
7216-95-7
Acute Tox. 4 STOT RE 2
Eye Irrit. 2
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H332
H373 (inhalation)
H319
inhalation:
ATE = 1,5 mg/l (dusts or mists)’
‘607-735-00-1
N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid)
200-652-8
67-43-6
Acute Tox. 4 STOT RE 2
Eye Irrit. 2
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H332
H373 (inhalation)
H319
inhalation:
ATE = 1,5 mg/l (dusts or mists)’
‘607-736-00-7
pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate
205-391-3
140-01-2
Acute Tox. 4
STOT RE 2
H332
H373 (inhalation)
GHS08
GHS07
Dgr
H332
H373 (inhalation)
inhalation:
ATE = 1,5 mg/l (dusts or mists)’
‘607-737-00-2
diisohexyl phthalate
276-090-2
71850-09-4
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘608-069-00-4
fludioxonil (ISO); 4-(2,2-difluoro-1,3-benzodioxol-4-yl)-1H-pyrrole-3-carbonitrile
—
131341-86-1
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 10’
‘613-329-00-5
halosulfuron-methyl (ISO);
methyl 3-chloro-5-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-1-methyl-1H-pyrazole-4-carboxylate
—
100784-20-1
Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410
M = 1000
M = 1000’
613-330-00-0
2-methylimidazole
211-765-7
693-98-1
Repr. 1B
H360Df
GHS08
Dgr
H360Df
‘616-225-00-8
(RS)-2-methoxy-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide; mandestrobin
—
173662-97-0
Aquatic Acute 1 Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 10’
‘616-226-00-3
carboxin (ISO);
2-methyl-N-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide; 5,6-dihydro-2-methyl-1,4-oxathiine-3-carboxanilide
226-031-1
5234-68-4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373 (kidneys)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (kidneys)
H317
H410
M = 1
M = 1’
‘616-227-00-9
metaflumizone (ISO); ( EZ )-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [ E -isomer ≥ 90 %, Z -isomer ≤ 10 % relative content]; [1]
( E )-2’-[2-(4-cyanophenyl)-1-(α,α,α -trifluoro-m-tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl]carbanilohydrazide [2]
—
139968-49-3 [1]
852403-68-0 [2]
Repr. 2
Lact.
STOT RE 2
H361fd
H362
H373
GHS08
Wng
H361fd
H362
H373’
‘650-056-00-0
dibutylbis(pentane-2,4-dionato-O,O’)tin
245-152-0
22673-19-4
Repr. 1B
STOT RE 1
H360FD
H372 (immune system)
GHS08
Dgr
H360FD
H372 (immune system)’.